Medtronic (NYSE:MDT) this week won CE Mark approval in the European Union for combined treatment with its Endurant II or IIs stent graft and the Heli-FX EndoAnchor system in patients with short aortic anatomies.
The combined treatment is now cleared with indications to that patients with aortic neck lengths down to 4mm with a less than or equal to 60 degree infra-renal angulation, according to a Medtronic spokesperson.
Medtronic touted the combined therapy as the first AAA short neck solution which is independent of renal stenting.
The Fridley, Minn.-based company said the new indication was formally launched in the European Union this week.
Earlier this week, Medtronic was reported to have acquired gastrointestinal disorder diagnostic company Crospon in a deal that could be worth as much as $45 million.
